Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-03 03:37:25 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Weight loss drug costs may need more research, senator suggests

hotspot

WSS

Astellas still sees hope in its gene therapy after four deaths

FDA's Woodcock to retire early next year

A new House health package & hospitals’ new site

Readout LOUD podcast: A CRISPR milestone, biotech mixology

The 10 drugs up first for Medicare price negotiation

Astellas still sees hope in its gene therapy after four deaths

leisure time

Wikipedia

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A new House health package & hospitals’ new site

Moonlake's readout produced a cash windfall. Risks remain

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Virginia high school admissions case could be legal follow

Advances in CAR

Bright Health sells Medicare Advantage business to Molina

Stem cell treatment guidelines are released by FDA

Bright Health sells Medicare Advantage business to Molina

NIH nominee Bertagnolli will get October confirmation hearing

focus

Gain of function research would be limited under House proposal

Weight loss drug costs may need more research, senator suggests

NYU radiologists take on the challenge of expensive MRI machines

Illumina names Agilent executive as new CEO

Does good food count as health care? Study aims to find out

Astellas still sees hope in its gene therapy after four deaths

Wikipedia

explore

hotspot

hotspot